HD IL-2 as an intermittent bolus infusion therapy has been tested in clinical trials for different tumor types [9–11] and is FDA-approved for the treatment of metastatic renal cell carcinoma and melanoma [8, 12, 13]. This evidence concerns the gene IL2 and melanoma.